For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Alignment Healthcare Inc (NASDAQ: ALHC) was $18.78 for the day, down -1.93% from the previous closing price of $19.15. In other words, the price has decreased by -$1.93 from its previous closing price. On the day, 2.73 million shares were traded. ALHC stock price reached its highest trading level at $19.03 during the session, while it also had its lowest trading level at $18.395.
Ratios:
Our analysis of ALHC’s different ratios will help us gain a deeper understanding of the company. In the meantime, Its Debt-to-Equity ratio is 2.04 whereas as Long-Term Debt/Eq ratio is at 2.04.
On October 14, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $21. KeyBanc Capital Markets Upgraded its Sector Weight to Overweight on August 25, 2025, while the target price for the stock was maintained at $21.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 24 ’25 when Robert Scavo bought 68,000 shares for $20.19 per share.
Christopher Joyce bought 15,000 shares of ALHC for $302,850 on Dec 24 ’25. On Dec 24 ’25, another insider, Dawn Maroney, who serves as the President of the company, bought 275,000 shares for $20.19 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALHC now has a Market Capitalization of 3757723136 and an Enterprise Value of 3443300864. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.03 while its Price-to-Book (P/B) ratio in mrq is 23.20. Its current Enterprise Value per Revenue stands at 0.947 whereas that against EBITDA is 97.109.
Stock Price History:
The Beta on a monthly basis for ALHC is 1.16, which has changed by 0.68279564 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, ALHC has reached a high of $21.06, while it has fallen to a 52-week low of $10.54. The 50-Day Moving Average of the stock is 3.89%, while the 200-Day Moving Average is calculated to be 15.11%.
Shares Statistics:
ALHC traded an average of 2.60M shares per day over the past three months and 2795530 shares per day over the past ten days. A total of 199.99M shares are outstanding, with a floating share count of 172.62M. Insiders hold about 13.73% of the company’s shares, while institutions hold 87.24% stake in the company. Shares short for ALHC as of 1765756800 were 16037111 with a Short Ratio of 6.18, compared to 1763078400 on 13982386. Therefore, it implies a Short% of Shares Outstanding of 16037111 and a Short% of Float of 12.280000000000001.
Earnings Estimates
The stock of Alignment Healthcare Inc (ALHC) is currently in the spotlight, with 4.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.02, with high estimates of $0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.28 and $0.19 for the fiscal current year, implying an average EPS of $0.23. EPS for the following year is $0.41, with 4.0 analysts recommending between $0.46 and $0.35.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 11 analysts. It ranges from a high estimate of $1.01B to a low estimate of $998.6M. As of. The current estimate, Alignment Healthcare Inc’s year-ago sales were $701.24MFor the next quarter, 11 analysts are estimating revenue of $1.22B. There is a high estimate of $1.28B for the next quarter, whereas the lowest estimate is $1.17B.
A total of 11 analysts have provided revenue estimates for ALHC’s current fiscal year. The highest revenue estimate was $3.95B, while the lowest revenue estimate was $3.93B, resulting in an average revenue estimate of $3.94B. In the same quarter a year ago, actual revenue was $2.7BBased on 11 analysts’ estimates, the company’s revenue will be $5.14B in the next fiscal year. The high estimate is $5.39B and the low estimate is $4.93B.
